Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will be held at the Westin St. Francis Hotel in San Francisco, California.
The company's management will deliver a presentation on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one meetings with investors. The presentation will be accessible via a live audio webcast on Erasca.com/events, with a replay available for 30 days following the event.
Erasca specializes in discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca (Nasdaq: ERAS), un'azienda di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione al 43° Congresso Annuale J.P. Morgan Healthcare. Il convegno si terrà presso il Westin St. Francis Hotel a San Francisco, California.
La direzione dell'azienda presenterà un intervento martedì 14 gennaio 2025, alle 9:45 ora del Pacifico e parteciperà a incontri one-to-one con gli investitori. La presentazione sarà disponibile tramite una trasmissione audio in diretta su Erasca.com/events, con una replica accessibile per 30 giorni dopo l'evento.
Erasca si specializza nella scoperta, nello sviluppo e nella commercializzazione di terapie per i pazienti affetti da cancro guidato dalle vie RAS/MAPK.
Erasca (Nasdaq: ERAS), una empresa de oncología de precisión en etapa clínica, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. La conferencia se llevará a cabo en el Westin St. Francis Hotel en San Francisco, California.
La dirección de la empresa ofrecerá una presentación el martes 14 de enero de 2025, a las 9:45 a.m. hora del Pacífico y participará en reuniones uno a uno con inversores. La presentación estará disponible a través de una transmisión de audio en vivo en Erasca.com/events, con una repetición accesible durante 30 días después del evento.
Erasca se especializa en descubrir, desarrollar y comercializar terapias para pacientes con cánceres impulsados por las vías RAS/MAPK.
에라스카 (Nasdaq: ERAS), 임상 단계의 정밀 종양학 회사가 제43회 JP모건 헬스케어 컨퍼런스에 참석한다고 발표했습니다. 이 컨퍼런스는 미국 캘리포니아 샌프란시스코의 웨스틴 세인트 프랜시스 호텔에서 열립니다.
회사의 경영진은 2025년 1월 14일 화요일 오전 9시 45분 (태평양 표준시)에 발표를 진행하고 투자자들과 일대일 회의에 참여할 예정입니다. 발표는 Erasca.com/events에서 라이브 오디오 웹캐스트를 통해 접근 가능하며, 행사 후 30일 동안 재생할 수 있습니다.
Erasca는 RAS/MAPK 경로에 의해 유도된 암을 가진 환자를 위한 치료법을 발견하고 개발하며 상업화하는 데 전문화되어 있습니다.
Erasca (Nasdaq: ERAS), une entreprise de oncologie de précision en phase clinique, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. La conférence se déroulera à l'hôtel Westin St. Francis à San Francisco, Californie.
La direction de l'entreprise fera une présentation le mardi 14 janvier 2025, à 9h45 heure du Pacifique et participera à des réunions individuelles avec des investisseurs. La présentation sera accessible en direct via un webcast audio sur Erasca.com/events, avec une rediffusion disponible pendant 30 jours après l'événement.
Erasca se spécialise dans la découverte, le développement et la commercialisation de thérapies pour les patients atteints de cancers induits par les voies RAS/MAPK.
Erasca (Nasdaq: ERAS), ein Unternehmen für präzise Onkologie in der klinischen Phase, hat seine Teilnahme an der 43. J.P. Morgan Healthcare-Konferenz angekündigt. Die Konferenz findet im Westin St. Francis Hotel in San Francisco, Kalifornien, statt.
Die Unternehmensleitung wird am Dienstag, den 14. Januar 2025, um 9:45 Uhr Pazifischer Zeit eine Präsentation halten und an persönlichen Gesprächen mit Investoren teilnehmen. Die Präsentation wird über einen Live-Audio-Webcast auf Erasca.com/events zugänglich sein, mit einer Wiederholung, die 30 Tage nach der Veranstaltung verfügbar ist.
Erasca hat sich auf die Entdeckung, Entwicklung und Kommerzialisierung von Therapien für Patienten mit RAS/MAPK-wegbetriebenen Krebserkrankungen spezialisiert.
- None.
- None.
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will present on Tuesday, January 14, 2025, at 9:45 am Pacific Time and will also participate in one-on-one investor meetings.
A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipelines in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
FAQ
When is Erasca (ERAS) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access Erasca's (ERAS) J.P. Morgan Healthcare Conference presentation?
What type of cancer treatments does Erasca (ERAS) focus on developing?
Will Erasca (ERAS) management be available for individual investor meetings at the J.P. Morgan conference?
